ADT Linked to Higher Alzheimer’s and Dementia Risk in Older Prostate Cancer Patients, Study Suggests

ADT Linked to Higher Alzheimer’s and Dementia Risk in Older Prostate Cancer Patients, Study Suggests
Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male hormones — may be more likely to develop Alzheimer's disease and dementia, a large database study reports. The study, "Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer," was published in JAMA Network Open. Androgen deprivation therapy has become a mainstay treatment for many prostate cancer patients, reducing the chances of cancer progression. But these approaches can have long-term adverse effects, including lower sexual function, reduced bone and cardiovascular health, as well as decreases in quality of life and functional status. Cognitive decline is one of the major concerns associated with long-term exposure to ADT. There are many explanations for why they may be linked, including the fact that lower levels of male hormones can increase the chances of other conditions that are known risk factors for Alzheimer's, such as diabetes, heart disease, depression, and loss of lean mass. Nevertheless, the possible association between long-term exposure to ADT and the risk of Alzheimer's and
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *